Moderate to severe plaque psoriasis may be a big part of your life, but it doesn’t have to define you.

Together with award-winning actor Ted Danson and others navigating this condition, we celebrate the strength of their inner vibe, the "it" factor that makes someone uniquely them. Watch the first episode featuring Ted and others impacted by plaque psoriasis.


With Ted & Emily

Ted Danson and SOTYKTU patient Emily discuss living with plaque psoriasis, focusing on personal
stories of resilience and self-advocacy.

Ted Danson interviews SOTYKTU™ patient Emily about living with moderate to severe plaque psoriasis

Ted is not taking SOTYKTU, and Emily is a real patient currently taking
SOTYKTU. Both participants have been compensated for their time.

View Transcript +

Psoriasis is an unscripted part of my life’s storyline. It’s not always comfortable, but it’s part of me. Through ‘SO, Have You Found It?’, I’m spotlighting the steps you can take to navigate this condition and celebrating the unique journeys of individuals managing plaque psoriasis.

– Ted Danson

Check back for new episodes

Ted Danson speaking with Emily, a patient living with moderate to severe plaque psoriasis
Ted Danson speaking with Emily, a patient living with moderate to severe plaque psoriasis

A path to self-empowerment

Your experience with plaque psoriasis is as unique as you are. Here are some ways to be a self-advocate:

Have candid conversations with your dermatologist about your condition

For more facts and resources to help inform those conversations, see below or visit

Connect with others and find strength in shared experiences through support groups

Explore treatment options, like SOTYKTU, with your dermatologist

Emily, a SOTYKTU™ (deucravacitinib) patient living with moderate to severe plaque psoriasis

Rethinking treatment for your moderate to severe plaque psoriasis?

Everyone’s experience is different, and a conversation with your dermatologist is the first step toward finding out if SOTYKTU, an FDA-approved medicine for adults with moderate to severe plaque psoriasis, is right for you.

Some facts to know when talking to your doctor:

Clear or almost clear skin was seen by half of people taking SOTYKTU

In one study, 50% of people taking SOTYKTU saw clear or almost clear skin vs 9% taking placebo at 16 weeks.

In the same study, skin clearance was also measured in a different way. A majority of people taking SOTYKTU saw 75% clearer skin vs those taking placebo (53% vs 9%).

In two studies of people with moderate to severe plaque psoriasis including 1,684 adults, 841 people received SOTYKTU, 422 received Otezla® (apremilast), and 421 received placebo. Patients were assessed at 16, 24, and 52 weeks.

SOTYKTU is the better pill for clearer skin

Almost twice as many people had 90% clearer skin
with SOTYKTU compared to the leading pill.*

AT 24 WEEKS. In one study, 42% of people taking SOTYKTU saw 90% clearer skin vs 22% taking the leading pill.* In a second study, 32% of people taking SOTYKTU saw 90% clearer skin vs 20% taking the leading pill.*

Please see the most common side effects for SOTYKTU here.

SOTYKTU™ (deucravacitinib) 6mg pill SOTYKTU™ (deucravacitinib) 6mg pill

SOTYKTU is the first of its kind once-daily pill

It can be taken wherever you are, with or without food and at any time that fits your schedule best.

*Otezla® (apremilast).
Selective TYK2 inhibitor.

There's only one SOTYKTU, so ask for it by name.

Learn more about SOTYKTU and find resources for
discussing treatment with your dermatologist


An introduction to SOTYKTU
featuring trial results, safety
information, how it works,
and more.



Make your next dermatologist appointment your best one yet with this guide. It’s perfect for jotting down notes before, during, or after a chat with your doctor.



Take a look at the efficacy and
safety results of SOTYKTU.





Whether you’re considering SOTYKTU and want to know what’s available to you or you’ve started on SOTYKTU and are interested in support materials that may help you along your treatment path, look here for downloadable resources and information to help.

SOTYKTU and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
Otezla is a registered trademark of Amgen Inc.
© 2024 Bristol-Myers Squibb Company.
1787-US-2400084 03/24
This website is intended for U.S. residents
18 years of age or older.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.